Diabetes Type 2
Conditions
Brief summary
Randomized, controlled, pragmatic trial with open-label extension evaluating BT-001, an investigational digital therapeutic intended to help patients with type 2 diabetes improve their glycemic control.
Detailed description
The study intervention, BT-001 (the App), will be dispensed at enrollment to the Immediate Intervention App Use arm of the trial. Patients randomized to the Delayed Intervention App Use arm will be provided a control App with diabetes control, and then the BT-001 App after 180 days. Each participant is assigned to one 90-day treatment cycle of BT-001. Over the 12-month intervention period, study participants will be able to opt into up to 3 additional treatment cycles of BT-001. Study schema is included at the end of this section
Interventions
DEVICEBT-001
BT-001is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone. The behavioral intervention process involves: Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs. Each week, BT-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily.
DEVICEControl Mobile Application
The app asks patients brief questions about their health but does not include any behavioral therapy.
Sponsors
Massachusetts General Hospital
Better Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
open label
Intervention model description
The study population consists of approximately 500 total participants, ages 18 - 75 years old, inclusive, who have type 2 diabetes. They will be randomized to the treatment or control group at a 3:1 ratio
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Current (within 3 months prior to enrollment) HbA1c \>=7.01% * Possession of and ability to use Android or iPhone mobile phone * Speaks and reads in English * Willing to measure frequent fasting finger glucose measurements as part of the App utilization
Exclusion criteria
* Current use of insulin other than a long-acting insulin analogue or human NPH insulin * HbA1c \>=11% * Cognitive impairment or degenerative neuropsychiatric condition (e.g. Alzheimer's, dementia, mixed dementia, other significant memory loss, schizophrenia), or any other condition that in the Investigator's opinion may prevent patient from completing study activities * Any terminal medical condition with life expectancy of \< 1 year.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in HbA1c | Baseline and Day 180 | Change in HbA1c from baseline (enrollment) to 6 months after enrollment between groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in HbA1c | Baseline and day 180, 365 | Change in HbA1c from baseline (enrollment) and from 6 months, to 12 months after enrollment between groups |
| Significant change in HbA1c | Baseline and Day 365 | Proportion of patients with a ≥ 0.4% decrease in HbA1c at 12 months within each study group |
Countries
United States
Outcome results
None listed